サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1787189

mRNA合成原料の世界市場

mRNA Synthesis Raw Materials

出版日
ページ情報
英文 278 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.66円
mRNA合成原料の世界市場
出版日: 2025年08月08日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 278 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

mRNA合成原料の世界市場は2030年までに20億米ドルに到達

2024年に17億米ドルと推定されるmRNA合成原料の世界市場は、2024年から2030年にかけてCAGR 2.5%で成長し、2030年には20億米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるキャッピング剤は、CAGR 3.1%を記録し、分析期間終了時には7億1,130万米ドルに達すると予想されます。ヌクレオチドセグメントの成長率は、分析期間中CAGR 2.7%と推定されます。

米国市場は4億6,780万米ドルと推定、中国はCAGR4.7%で成長予測

米国のmRNA合成原料市場は、2024年に4億6,780万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに3億8,030万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは4.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.0％と2.2％と予測されています。欧州では、ドイツがCAGR 1.5%で成長すると予測されています。

世界のmRNA合成原料市場- 主要動向と促進要因のまとめ

mRNA合成原料は治療薬の次のフロンティアをどのように促進するか？

mRNAベース技術の急速な進歩により、メッセンジャーRNA（mRNA）の合成に不可欠な高純度でスケーラブルな原材料の需要が高まっています。これらの原料には、ヌクレオチド、酵素、キャッピング試薬、脂質ナノ粒子（LNP）などが含まれ、これらはすべてmRNA治療薬やワクチンの安定性、有効性、製造可能性を確保する上で重要な役割を果たしています。mRNAワクチンCOVID-19の前例のない成功は、mRNA技術の変革の可能性を示し、がん、遺伝性疾患、感染症の治療法開発への投資に拍車をかけた。従来の生物製剤とは異なり、mRNAベースの医薬品は合成原料に依存するため、複雑な細胞培養システムを必要とせず、迅速な拡張が可能です。個別化医療や遺伝子編集療法の急増は、研究者がタンパク質発現や免疫応答調節を強化するためにmRNA構築物を最適化しようと努力するため、高品質の原料に対する需要をさらに増幅させています。さらに、mRNAに基づく研究がワクチンだけでなく、タンパク質代替療法や再生医療にまで拡大したことで、応用範囲が広がり、厳格な品質管理と規制に準拠した製造プロセスが必要とされています。バイオテクノロジー企業やCDMO（開発・製造受託機関）がコスト効率と収率の高いmRNA生産の最適化を競い合う中、原材料の革新、純度基準、サプライチェーンの弾力性への注目は、これまで以上に重要になっています。

どのような技術革新がmRNA合成サプライチェーンを再構築しているのか？

技術の進歩は、mRNA生産に必要な原材料の合成と最適化を大きく変え、効率性、拡張性、規制遵守の向上に道を開いています。最も重要なブレークスルーのひとつは、体外転写（IVT）プロセスの最適化であり、バクテリオファージRNAポリメラーゼを用いた酵素合成は、二本鎖RNA（dsRNA）の混入を最小限に抑え、より高いmRNA純度が得られるように微調整されてきました。酵素的キャッピングやCleanCap（R）技術を用いた共転写キャッピングなどの改良されたキャッピング戦略により、mRNAの安定性と翻訳効率が向上しました。さらに、N1-メチルシュードウリジンのような化学修飾ヌクレオチドの技術革新は、治療効果を向上させる一方で免疫原性を著しく低下させています。脂質ナノ粒子（LNP）送達システムも大きな進歩を遂げており、イオン化可能な脂質は、より高い生体適合性、標的組織への送達、標的外影響の低減のために設計されています。ヌクレオシド三リン酸（NTP）の合成と精製の自動化は、バッチ間の一貫性を向上させ、生産のボトルネックを減らし、大規模なmRNA製造を可能にしました。さらに、製剤設計におけるAI主導の予測モデリングの統合は、さまざまな治療用途に向けたmRNA構築物の迅速な最適化を促進しました。このような技術的改善により、mRNAの収量、安定性、送達が一挙に向上し、研究機関と製薬メーカー双方の増大する需要に原料が確実に応えられるようになりました。

なぜmRNA原料の生産には規制当局の監視とサプライチェーンの強靭性が不可欠なのか？

mRNA治療薬業界の急速な拡大により、原材料の調達と生産における規制当局の監督とサプライチェーンの安定性の重要性が高まっています。FDAやEMAなどの規制機関は、mRNA合成に使用される原材料の純度、一貫性、トレーサビリティに関するガイドラインを厳格化し、適正製造基準（GMP）の遵守を徹底しています。このため、特にヌクレオチド、キャッピング試薬、脂質賦形剤の調達と精製において、厳格な品質管理対策が必要となっています。シングルユース・バイオプロセシング技術の採用が進むにつれ、製造ワークフローが合理化され、交差汚染のリスクが減少し、高スループットmRNA製造の効率が向上しています。しかし、mRNA原料の世界サプライチェーンは、主要試薬や脂質の不足でワクチン製造が遅れたCOVID-19のパンデミック時に見られたように、依然として混乱に脆弱です。このため製薬会社は、地政学的リスクや物流のボトルネックを軽減するため、垂直統合型サプライチェーンへの投資や地域製造ハブの設立を進めています。さらに、バイオテクノロジー企業と化学品サプライヤーとの提携が強化され、高品質のmRNA前駆体専用の生産施設の設立につながっています。mRNAベースのワクチンや治療に対する世界の需要が拡大し続ける中、この画期的な技術の勢いを持続させるためには、弾力性がありコンプライアンスに準拠したサプライチェーンを確保することが最も重要です。

mRNA合成原料市場を促進する主な成長要因は何か？

mRNA合成原料市場の成長は、mRNAベースの治療薬の拡大、バイオテクノロジー研究開発への投資の増加、原料精製および製剤化技術の進歩など、いくつかの要因によって牽引されています。mRNAワクチンの成功は、がん免疫療法、希少疾患治療、タンパク質代替療法など、新たな用途の研究に拍車をかけており、これらすべてにおいて発現と安定性を最適化するための特殊な原材料が必要とされています。mRNAベースの薬剤を含む臨床試験の急増は、高純度ヌクレオチド、酵素試薬、脂質キャリアの需要も高めており、サプライヤーは生産能力を拡大する必要に迫られています。さらに、自己増幅型mRNA（saRNA）および環状RNA（circRNA）技術の出現は、技術革新の新たな道を開き、新規原料組成の必要性を促進しています。mRNA製剤開発におけるAI主導の薬剤設計とハイスループットスクリーニングの採用拡大が、精密工学的原材料の需要をさらに加速しています。さらに、ワクチン製造の世界の分散化と核酸治療薬に特化したCDMOの台頭によりサプライチェーンが強化され、mRNA前駆体の迅速な生産と供給が可能になりました。mRNA療法を個々の患者に合わせる個別化医療への注目の高まりも市場拡大に寄与しており、修飾ヌクレオチドや脂質キャリアのカスタム合成が必要とされています。政府や製薬会社がパンデミック対策や次世代ワクチンへの投資を続ける中、高品質でスケーラブル、かつ規制に準拠したmRNA原料の需要は持続的な成長が見込まれ、現代バイオテクノロジーの要としての役割を確固たるものにしています。

セグメント

製品タイプ（キャッピング剤、ヌクレオチド、プラスミドDNA、酵素、その他のタイプ）、用途（ワクチン製造用途、治療薬製造用途、その他の用途）、最終用途（バイオ医薬品・製薬企業最終用途、CRO・CMO最終用途、学術・研究機関最終用途）

調査対象企業の例

  • Aldevron
  • BioNTech SE
  • Bio-Synthesis Inc.
  • BOC Sciences
  • Creative Biogene
  • CureVac N.V.
  • Eurogentec
  • F. Hoffmann-La Roche Ltd.
  • HONGENE
  • Jena Bioscience GmbH
  • Lucigen Corporation
  • Maravai LifeSciences
  • Merck KGaA
  • Moderna, Inc.
  • New England Biolabs
  • Promega Corporation
  • Sigma-Aldrich（MilliporeSigma）
  • Thermo Fisher Scientific, Inc.
  • TriLink BioTechnologies
  • Yeasen Biotechnology（Shanghai）Co., Ltd.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP32235

Global mRNA Synthesis Raw Materials Market to Reach US$2.0 Billion by 2030

The global market for mRNA Synthesis Raw Materials estimated at US$1.7 Billion in the year 2024, is expected to reach US$2.0 Billion by 2030, growing at a CAGR of 2.5% over the analysis period 2024-2030. Capping Agents, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$711.3 Million by the end of the analysis period. Growth in the Nucleotides segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$467.8 Million While China is Forecast to Grow at 4.7% CAGR

The mRNA Synthesis Raw Materials market in the U.S. is estimated at US$467.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$380.3 Million by the year 2030 trailing a CAGR of 4.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global mRNA Synthesis Raw Materials Market - Key Trends & Drivers Summarized

How Are mRNA Synthesis Raw Materials Powering the Next Frontier of Therapeutics?

The rapid advancement of mRNA-based technologies has propelled the demand for high-purity and scalable raw materials essential for the synthesis of messenger RNA (mRNA). These raw materials include nucleotides, enzymes, capping reagents, and lipid nanoparticles (LNPs), all of which play a crucial role in ensuring the stability, efficacy, and manufacturability of mRNA therapeutics and vaccines. The unprecedented success of mRNA COVID-19 vaccines demonstrated the transformative potential of mRNA technology, spurring investments in developing treatments for cancer, genetic disorders, and infectious diseases. Unlike traditional biologics, mRNA-based drugs rely on synthetic raw materials, eliminating the need for complex cell culture systems and enabling rapid scalability. The surge in personalized medicine and gene editing therapies has further amplified the demand for high-quality raw materials, as researchers strive to optimize mRNA constructs for enhanced protein expression and immune response modulation. Additionally, the expansion of mRNA-based research beyond vaccines into protein replacement therapies and regenerative medicine has broadened the scope of applications, necessitating stringent quality controls and regulatory-compliant manufacturing processes. As biotechnology companies and CDMOs (Contract Development and Manufacturing Organizations) race to optimize cost-effective and high-yield mRNA production, the focus on raw material innovation, purity standards, and supply chain resilience has become more critical than ever.

What Technological Innovations Are Reshaping the mRNA Synthesis Supply Chain?

Technological advancements have significantly transformed the synthesis and optimization of raw materials required for mRNA production, paving the way for increased efficiency, scalability, and regulatory compliance. One of the most critical breakthroughs has been the optimization of in vitro transcription (IVT) processes, where enzymatic synthesis using bacteriophage RNA polymerases has been fine-tuned to yield higher mRNA purity with minimal double-stranded RNA (dsRNA) contaminants. Improved capping strategies, such as enzymatic capping and co-transcriptional capping using CleanCap® technology, have enhanced mRNA stability and translational efficiency. Additionally, innovations in chemically modified nucleotides, such as N1-methylpseudouridine, have significantly reduced immunogenicity while improving therapeutic efficacy. The lipid nanoparticle (LNP) delivery system has also undergone significant advancements, with ionizable lipids being engineered for greater biocompatibility, targeted tissue delivery, and reduced off-target effects. The automation of nucleoside triphosphate (NTP) synthesis and purification has improved batch-to-batch consistency, reducing production bottlenecks and enabling large-scale mRNA manufacturing. Furthermore, the integration of AI-driven predictive modeling in formulation design has facilitated rapid optimization of mRNA constructs for different therapeutic applications. These technological improvements have collectively enhanced mRNA yield, stability, and delivery, ensuring that raw materials meet the growing demands of both research institutions and pharmaceutical manufacturers.

Why Is Regulatory Oversight and Supply Chain Resilience Critical for mRNA Raw Material Production?

The rapid expansion of the mRNA therapeutics industry has heightened the importance of regulatory oversight and supply chain stability in the procurement and production of raw materials. Regulatory agencies such as the FDA and EMA have tightened guidelines for the purity, consistency, and traceability of raw materials used in mRNA synthesis, ensuring compliance with Good Manufacturing Practices (GMP). This has necessitated rigorous quality control measures, particularly in the sourcing and purification of nucleotides, capping reagents, and lipid excipients. The increasing adoption of single-use bioprocessing technologies has streamlined production workflows, reducing the risk of cross-contamination and improving efficiency in high-throughput mRNA manufacturing. However, the global supply chain for mRNA raw materials remains vulnerable to disruptions, as seen during the COVID-19 pandemic, when shortages of key reagents and lipids delayed vaccine production. This has prompted pharmaceutical companies to invest in vertically integrated supply chains and establish regional manufacturing hubs to mitigate geopolitical risks and logistical bottlenecks. Additionally, partnerships between biotech firms and chemical suppliers have intensified, leading to the establishment of dedicated production facilities for high-quality mRNA precursors. As global demand for mRNA-based vaccines and therapies continues to grow, ensuring a resilient and compliant supply chain will be paramount in sustaining the momentum of this groundbreaking technology.

What Are the Key Growth Drivers Propelling the mRNA Synthesis Raw Materials Market?

The growth in the mRNA synthesis raw materials market is driven by several factors, including the expansion of mRNA-based therapeutics, increasing investments in biotechnology R&D, and advancements in raw material purification and formulation technologies. The success of mRNA vaccines has fueled research into new applications, including cancer immunotherapy, rare disease treatments, and protein replacement therapies, all of which require specialized raw materials for optimized expression and stability. The surge in clinical trials involving mRNA-based drugs has also heightened the demand for high-purity nucleotides, enzymatic reagents, and lipid carriers, prompting suppliers to scale up production capabilities. Additionally, the emergence of self-amplifying mRNA (saRNA) and circular RNA (circRNA) technologies has opened new avenues for innovation, driving the need for novel raw material compositions. The growing adoption of AI-driven drug design and high-throughput screening in mRNA formulation development has further accelerated the demand for precision-engineered raw materials. Moreover, the global shift toward decentralized vaccine manufacturing and the rise of CDMOs specializing in nucleic acid therapeutics have strengthened the supply chain, enabling faster production and delivery of mRNA precursors. The increasing focus on personalized medicine, where mRNA therapies are tailored to individual patients, has also contributed to market expansion, necessitating custom synthesis of modified nucleotides and lipid carriers. As governments and pharmaceutical companies continue to invest in pandemic preparedness and next-generation vaccines, the demand for high-quality, scalable, and regulatory-compliant mRNA raw materials is expected to witness sustained growth, solidifying their role as a cornerstone of modern biotechnology.

SCOPE OF STUDY:

The report analyzes the mRNA Synthesis Raw Materials market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Capping Agents, Nucleotides, Plasmid DNA, Enzymes, Other Types); Application (Vaccine Production Application, Therapeutics Production Application, Other Applications); End-Use (Biopharmaceutical & Pharmaceutical Companies End-Use, CROs & CMOs End-Use, Academic & Research Institutes End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Aldevron
  • BioNTech SE
  • Bio-Synthesis Inc.
  • BOC Sciences
  • Creative Biogene
  • CureVac N.V.
  • Eurogentec
  • F. Hoffmann-La Roche Ltd.
  • HONGENE
  • Jena Bioscience GmbH
  • Lucigen Corporation
  • Maravai LifeSciences
  • Merck KGaA
  • Moderna, Inc.
  • New England Biolabs
  • Promega Corporation
  • Sigma-Aldrich (MilliporeSigma)
  • Thermo Fisher Scientific, Inc.
  • TriLink BioTechnologies
  • Yeasen Biotechnology (Shanghai) Co., Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • mRNA Synthesis Raw Materials - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Surge in mRNA Vaccine Development Drives Accelerated Demand for Raw Materials in mRNA Synthesis
    • Expanding Investment in Biotechnology and Pharmaceutical R&D Strengthens Market for mRNA Synthesis Raw Materials
    • Rising Need for mRNA-Based Therapeutics and Vaccines Expands Market Opportunities for Raw Material Suppliers
    • Technological Advancements in mRNA Synthesis Techniques Propel Demand for High-quality Raw Materials
    • Increasing Government Funding for mRNA Research and Vaccine Development Generates Growth in Raw Material Requirements
    • Expansion of mRNA Vaccine Manufacturing Capacity Strengthens Business Case for Scaling Raw Material Production
    • Rising Demand for Personalized Medicine and mRNA Therapies Expands Addressable Market for Synthesis Raw Materials
    • Regulatory Support and Accelerated Approval Processes for mRNA Vaccines Increase Raw Material Procurement and Usage
    • The Rise in Global Health Initiatives and Vaccination Programs Expands the Market for mRNA Synthesis Raw Materials
    • Advancements in Raw Material Purification and Synthesis Technologies Drive Efficiency and Cost Reduction in mRNA Production
    • Surge in mRNA-based COVID-19 Vaccine Production Fuels Long-term Demand for mRNA Synthesis Raw Materials
    • Growth in Research Institutions and Academic Labs Investing in mRNA Technology Propels Raw Material Demand
    • The Emergence of mRNA Therapies Beyond Vaccines Drives Innovation and Expands the Market for Specialized Raw Materials
    • Increasing Integration of mRNA Synthesis into Cancer Immunotherapy Research Expands Market Opportunity for Raw Materials
    • Expanding Production Facilities for mRNA-Based Products Strengthens Market for Essential Raw Materials in Large-scale Synthesis
    • Rising Demand for RNA Modifications and Specialized Reagents Drives New Opportunities for Raw Material Suppliers
    • Technological Innovation in Nucleotide Synthesis and Purification Enhances the Quality and Availability of mRNA Raw Materials
    • Growing Focus on Sustainable and Cost-effective mRNA Production Methods Expands Market for Raw Materials with Reduced Environmental Impact
    • Increasing Competitive Landscape Among Biopharma Companies Strengthens the Demand for Reliable and High-purity Raw Materials
    • Growing Collaboration Between mRNA Developers and Raw Material Providers Drives Long-term Supply Chain Stability and Innovation
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World mRNA Synthesis Raw Materials Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for mRNA Synthesis Raw Materials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Capping Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Capping Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Nucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Nucleotides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Plasmid DNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Plasmid DNA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Enzymes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Enzymes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for CROs & CMOs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for CROs & CMOs End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Biopharmaceutical & Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Biopharmaceutical & Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Vaccine Production Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Vaccine Production Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Therapeutics Production Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Therapeutics Production Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • mRNA Synthesis Raw Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • JAPAN
    • mRNA Synthesis Raw Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 42: Japan Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • CHINA
    • mRNA Synthesis Raw Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 48: China Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • EUROPE
    • mRNA Synthesis Raw Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for mRNA Synthesis Raw Materials by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • FRANCE
    • mRNA Synthesis Raw Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 58: France Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • GERMANY
    • mRNA Synthesis Raw Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 64: Germany Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • ITALY
    • TABLE 70: Italy Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • UNITED KINGDOM
    • mRNA Synthesis Raw Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 76: UK Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • SPAIN
    • TABLE 82: Spain Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Spain 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 84: Spain Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Spain 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • RUSSIA
    • TABLE 88: Russia Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Russia 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 90: Russia Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Russia 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 94: Rest of Europe Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of Europe 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 96: Rest of Europe Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of Europe 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • ASIA-PACIFIC
    • mRNA Synthesis Raw Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 100: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 101: Asia-Pacific 6-Year Perspective for mRNA Synthesis Raw Materials by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2025 & 2030
    • TABLE 102: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Asia-Pacific 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 106: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Asia-Pacific 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • AUSTRALIA
    • mRNA Synthesis Raw Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 108: Australia Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Australia 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 112: Australia Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Australia 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • INDIA
    • mRNA Synthesis Raw Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 114: India Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 115: India 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 118: India Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 119: India 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • SOUTH KOREA
    • TABLE 120: South Korea Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 121: South Korea 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 124: South Korea Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 125: South Korea 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 126: Rest of Asia-Pacific Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 130: Rest of Asia-Pacific Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Rest of Asia-Pacific 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • LATIN AMERICA
    • mRNA Synthesis Raw Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 132: Latin America Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 133: Latin America 6-Year Perspective for mRNA Synthesis Raw Materials by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 136: Latin America Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Latin America 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 138: Latin America Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 139: Latin America 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 142: Argentina Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 143: Argentina 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 144: Argentina Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 145: Argentina 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 148: Brazil Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 149: Brazil 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 150: Brazil Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 151: Brazil 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 154: Mexico Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 155: Mexico 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 156: Mexico Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 157: Mexico 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 160: Rest of Latin America Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 161: Rest of Latin America 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 162: Rest of Latin America Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 163: Rest of Latin America 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • MIDDLE EAST
    • mRNA Synthesis Raw Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East 6-Year Perspective for mRNA Synthesis Raw Materials by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2025 & 2030
    • TABLE 166: Middle East Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 167: Middle East 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 168: Middle East Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 169: Middle East 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • IRAN
    • TABLE 172: Iran Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 173: Iran 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 174: Iran Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 175: Iran 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • ISRAEL
    • TABLE 178: Israel Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 179: Israel 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 180: Israel Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 181: Israel 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • SAUDI ARABIA
    • TABLE 184: Saudi Arabia Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 185: Saudi Arabia 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 186: Saudi Arabia Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 187: Saudi Arabia 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 190: UAE Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 191: UAE 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 192: UAE Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 193: UAE 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 196: Rest of Middle East Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 197: Rest of Middle East 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 198: Rest of Middle East Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 199: Rest of Middle East 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030
  • AFRICA
    • mRNA Synthesis Raw Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 202: Africa Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Type - Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 203: Africa 6-Year Perspective for mRNA Synthesis Raw Materials by Type - Percentage Breakdown of Value Sales for Capping Agents, Nucleotides, Plasmid DNA, Enzymes and Other Types for the Years 2025 & 2030
    • TABLE 204: Africa Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 205: Africa 6-Year Perspective for mRNA Synthesis Raw Materials by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for mRNA Synthesis Raw Materials by Application - Vaccine Production Application, Therapeutics Production Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa 6-Year Perspective for mRNA Synthesis Raw Materials by Application - Percentage Breakdown of Value Sales for Vaccine Production Application, Therapeutics Production Application and Other Applications for the Years 2025 & 2030

IV. COMPETITION